



Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Brisbane, Australia 29th November 2017: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to announce passing 50% recruitment in the VF00102 clinical trial.

Twice as many patients were enrolled in November than in the previous month, bringing the total number randomised to 84 out of a planned total of 168.

“The trial is on target to complete recruitment in the second quarter of 2018. Recruitment is accelerating thanks to our active management strategy and as our social media campaign comes fully on-line – and we are particularly pleased to see the spread of enrolment across our sites,” said Dr Ros Wilson, CEO of Factor Therapeutics.

“Venous leg ulcers represent a critical burden for patients and health care providers worldwide. Completing this trial is a key goal for Factor Therapeutics and we are excited to pass this important milestone,” commented Factor Therapeutics Chair, Dr Cherrell Hirst.

-ENDS-

Corporate Contact

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

Investor Relations Contact

Kyahn Williamson
Head of Investor Communication
WE Buchan
kwilliamson@we-buchan.com

About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>.